The QualityStocks Daily Wednesday, February 19th, 2020

Today's Top 3 Investment Newsletters

QualityStocks (DTRC) +103.05%

BUYINS.NET (ZOM) +79.64%

Penny Stock Titans (BRVO) +57.65%

The QualityStocks Daily Stock List

Armanino Foods of Distinction, Inc. (AMNF)

Zacks, Dividend Diplomats, Slater Sentinel, Super Stock Screener, Infront Analytics, MarketBeat, Morningstar, TMXmoney, Simply Wall St, MarketWatch, Market Screener, QSR Magazine, Capital Cube, OTC Markets, TalkMarkets, Glassdoor, StockInvest.us, Insider Financial, Wallet Investor, InvestorsHub, GuruFocus, Dividend.com, Dividend Investor, Stockopedia, TradingView, Seeking Alpha, and StockInvest.us reported earlier on Armanino Foods of Distinction, Inc. (AMNF), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Armanino Foods of Distinction, Inc. produces and markets frozen and refrigerated food products in the United States. The Company offers its products under the Armanino brand and it markets its products through a network of food brokers. In addition, it sells to retail and foodservice distributors, club-type stores, and industrial accounts. Formed in 1978, Armanino Foods of Distinction is based in Hayward, California.

The Company’s frozen products comprise pesto sauces, stuffed pastas, and pasta sheets. They also include Italian pastas and cooked meat products. Armanino Foods of Distinction also offers cooked beef and turkey meatballs, and cheese shakers, and cooked and uncooked frozen stuffed pastas. This includes meat, butternut squash, cheese ravioli and jumbo cheese, and jumbo mushroom ravioli. Furthermore, the Company offers jumbo cheese/spinach green dough ravioli; cheese ravioli; meat filled, tri-color cheese, and cheese tortellini; and tri-color cheese and cheese capelletti, manicotti, and stuffed shells.

In the Foodservice sector, Armanino Foods of Distinction is the industry’s leading source for premium frozen pesto. It is famous for its Basil Pesto. The Company also offers other flavors, including Cilantro, Dried Tomato & Garlic, Roasted Red Bell Pepper, Southwest Chipotle, Artichoke, Roasted Garlic, Creamy Garlic, Harissa, Romesco, Chimichurri, and Light Basil Pesto.

Last week, Armanino Foods of Distinction reported record-breaking Sales and Earnings for Q4 and for the year ended December 31, 2019. Net Sales for Q4 of 2019 were $10,929,061 versus $10,265,532 for the prior year. This represents an increase of 6 percent. Income Before Taxes for Q4 2019 were $1,795,737 versus $1,670,855 for the same quarter in 2018. This represents an increase of 7 percent. Net Income for this period increased to $1,422,805 (or $0.0444 per share), from $1,230,706 (or $0.0384 per share) for the prior year. This represents an increase of 16 percent.

Net Sales for the year ended December 31, 2019 were $42,551,202 versus $41,838,018 for 2018, an increase of 2 percent. Income Before Taxes for 2019 were $8,181,402, versus the 2018 figure of $8,126,086, an increase of 1 percent. Net Income for the year ended December 31, 2019 was $6,484,997 (or $0.2022 per share), versus $6,265,786 (or $0.1954 per share) for 2018. This represents an increase of 3 percent.

Armanino Foods of Distinction, Inc. (AMNF), closed Wednesday's trading session at $3.38, up 0.595238%, on 23,126 volume with 38 trades. The average volume for the last 3 months is 16,970 and the stock's 52-week low/high is $3.02999997/$3.79250001.

Basic Energy Services, Inc. (BASX)

Zacks, OilPrice.com, Slater Sentinel, OTC Markets, Street Insider, OTC.Watch, InvestorsHub, AI Stock Finder, Morningstar, QuantumOnline.com, Barchart, Dividend Investor, Stockwatch, GuruFocus, MarketWatch, PR Newswire, and Seeking Alpha reported beforehand on Basic Energy Services, Inc. (BASX), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Basic Energy Services, Inc. provides well site services to oil and natural gas drilling and producing companies in the United States. The Company supports six geographic markets conducting operations in the Texas Gulf Coast region, the Central region, the Permian Basin of West Texas, California and the Rocky Mountains. Its services include Well Servicing, Midstream Services, Water Logistics, Pumping Services, and Rental/Fishing Tools. OTCQX-listed, Basic Energy Services has its corporate office in Fort Worth, Texas.

The Company provides its services to a diverse group of greater than 2,000 oil and gas companies. Its operations are focused in liquids-rich basins that have historically exhibited strong drilling and production economics in recent years with a substantial presence in the Permian Basin, Powder River Basin, and the Bakken, Eagle Ford, and Denver-Julesburg shales.

Basic's Well Servicing operations leverage a contemporary fleet of high spec workover rigs, 24 hour rig packages and 700 rig series, matched to the needs of the local markets. The Company’s high spec well servicing rigs perform reliable services to maintain and improve production throughout the productive life of the well. Basic’s Water Logistics operations provides oilfield fluid supply, transportation, storage and disposal services required in workover, completion and remedial projects, as well as in daily producing well operations.

The Company’s Pumping Services include Hydraulic Fracturing; Cementing; Acidizing; Nitrogen; Coil Tubing; Water Solution Services; and Frac Stacs. In addition, its Midstream Services is now Agua Libre Midstream.

Moreover, Basic Energy Services has its network of 24 Rental & Fishing Tools facilities. The Company offers an extensive line-up of rental tools that range from the smallest to the largest and also a wide-ranging inventory of fishing tools.

Basic Energy Services announced this past December a plan to divest of its pumping services assets (not inclusive of coiled tubing) in manifold transactions with expected proceeds of about $30 to $45 million. The design of this divestiture is to bolster the Company’s core remaining production-focused businesses of well servicing and water logistics. This non-core divestiture will also fund the projected 2020 and 2021 capital budget of Agua Libre Midstream, Basic Energy Services’ fast growing, high return-on-assets business.

In December 2019, Basic Energy Services announced the appointment of Mr. Keith L. Schilling as President, Chief Executive Officer and Director, which was effective January 2, 2020. Mr. Schilling is an accomplished professional with more than 20 years of experience in senior managerial positions with major energy services companies. He replaced T.M. “Roe” Patterson in connection with his voluntary resignation. Before joining Basic Energy Services, Mr. Schilling was employed by Baker Hughes Company, where he served as President of Baker Hughes Canada since November 2018 and as Director, Sales and Commercial from July 2017 until November 2018.

Basic Energy Services, Inc. (BASX), closed Wednesday's trading session at $0.1929, up 5.4098%, on 8,788 volume with 16 trades. The average volume for the last 3 months is 500,671 and the stock's 52-week low/high is $0.150999993/$5.34000015.

Eyecarrot Innovations Corp. (EYCCF)

NetworkNewsWire, OTC Markets, Stock of the Week, Beat Penny Stocks, Penny Stock Hub, All Penny Stocks, InvestorX, GlobeNewswire, Market Screener, PR Newswire, Dividend.com, Dividend Investor, Simply Wall St, OTC.Watch, Street Insider, Proactive Investors, Investors Hangout, Stockwatch, Stockhouse, TheNewswire, InvisonMag, Morningstar, GuruFocus, Seeking Alpha, Proactive Investors, The Stock Market Watch, Wallet Investor, Market News Updates, Barchart, InvestorsHub, and Trading View reported earlier on Eyecarrot Innovations Corp. (EYCCF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Eyecarrot Innovations Corp. offers vision care practitioners with IT (Information Technology) solutions to measure and enhance oculomotor sensory performance. The Company is working to create a comprehensive software-based solution. Eyecarrot is at the vanguard of a new wave, leading the way in vision therapy and sports vision via unique technical solutions and valuable content, supported by recognized leaders in the profession. Eyecarrot Innovations’ shares trade on the OTC Markets Group’s OTCQB. The Company is based in Toronto, Ontario.

Eyecarrot Innovations’ Binovi™ Platform is an inventive technology solution. Binovi integrates software, hardware, data, and expert knowledge to help optometrists treat vision-related issues with in-office therapy and doctor-led home-based activities, and help trainers and athletes improve and maintain performance in sport and in life.

Binovi Pro is the central hub of Eyecarrot’s Binovi platform. An entity can combine Eyecarrot’s extensive library with their own custom activities to create and prescribe individualized home therapy plans that sync automatically with Binovi Coach. Binovi Coach encourages and galvanizes patients to confidently complete their prescribed home therapy with clarity and guidance.

Eyecarrot Innovations focuses on improving performance for all kinds of athletes. Binovi Touch is a purposeful and strong tool for vision therapy and vision training. Binovi Touch is the result of greater than three decades of experience in more than 500 practices in over 20 countries globally on children, athletes, and seniors resolving issues from development, to performance, to rehabilitation.

Earlier this month, Eyecarrot Innovations announced its participation within the Professional Football Strength & Conditioning Coaches Association (PFSCCA) Annual Coaches Summit February 24, 2020 in Indianapolis, Indiana. PFSCAA brings together the Head Strength Coaches of the NFL (National Football League) and their assistants, with the world’s foremost sports scientists and researchers along with the most advanced equipment companies and sports performance service providers via pioneering injury resiliency and sports performance training educational programs.

Mr. Adam Cegielski, Eyecarrot Innovations Founder and Chief Executive Officer, said, “Improving key vision skills is the next step in improving human performance, one that can have broad impacts both on and off the field. In a fast-paced sport like football, training anticipation, timing, and depth perception can be the difference between a quarterback making a game-winning touchdown pass, or being picked off. The Binovi Platform helps athletic trainers and their teams train athletes to improve these key vision skills and more.”

Last week, Eyecarrot Innovations announced that it entered into a share purchase agreement dated February 10, 2020 providing for the acquisition of ConnectMe Solution indirectly via the acquisition of Call Connect Me, Inc. from its security holders. ConnectMe is a lead delivery and monetization Software As A Service (SAAS) solution. It was developed by venture capitalist Raed Masri. The software-based sales solution will enable Eyecarrot to grow its revenues while decreasing sales operation costs as it drives the commercialization of its Binovi Platform product suite.

Eyecarrot Innovations Corp. (EYCCF), closed Wednesday's trading session at $0.45, off by 4.4322%, on 930 volume with 7 trades. The average volume for the last 3 months is 10,810 and the stock's 52-week low/high is $0.009999999/$0.552799999.

Greene Concepts, Inc. (INKW)

Market Wire News, OTC Markets, OTC Dynamics, Pink Investing, OTC PR Wire, Stock Reads, Pink Investing, All Cap Research, Street Insider, GlobeNewswire, Investors Observer, Market Screener, EIN Presswire, Morningstar, Seeking Alpha, Dividend Investor, Stockwatch, and TradingView reported previously on Greene Concepts, Inc. (INKW), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Greene Concepts, Inc. is an emerging leader in the global scientifically formulated beverage industry. Via its recently acquired wholly-owned subsidiary, Mammoth Ventures, Inc., the Company has entered into the specialty beverage and bottling business. Greene Concepts is based in Clovis, California. The Company’s shares trade on the OTC Markets.

Greene Concepts has completed the 100 percent acquisition of Mammoth Ventures. Mammoth is a holding company that includes the 60,000 sq. ft. beverage and bottling facility located just outside of Asheville, North Carolina. Furthermore, this acquisition of the holding company includes the building, all bottling equipment, fixtures, inventory and any and all other assets held and owned by Mammoth Ventures, Inc.

This facility will concentrate on an array of beverage product lines. These include, but are not limited to, CBD (cannabidiol) infused beverages, spring and artesian water, as well as enhanced athletic drinks in addition to other product offerings.

Along with domestic market growth, Greene Concepts plans for expansion into the fast growing Southeast Asia market. This includes Singapore, Indonesia, Thailand, Malaysia and Vietnam. Indonesia represents the largest market in the region. It is the fourth largest national population worldwide.

Last week, Greene Concepts announced that it is maximizing additional capacity of its 60,000 square foot manufacturing plant to offer business opportunities to third-party beverage companies by way of white label production. This allows the Company to produce ready-to-drink (RTD) beverages and bottled water for the third party company using the other company's product name, formulation and product labels for a value-added fee.

Greene Concepts continues to and is now actively seeking and negotiating with a number of large water and beverage players within the industry to either partner with or collaborate with concerning ready-to-drink (RTD) beverages and white label bottled water. The white labeling business model refers to a fully supported product or service that is made by one company but sold by another.

Greene Concepts, Inc. (INKW), closed Wednesday's trading session at $0.002, even for the day, on 1,519,499 volume with 23 trades. The average volume for the last 3 months is 3,745,413 and the stock's 52-week low/high is $0.00179/$0.034499999.

PASSUR Aerospace, Inc. (PSSR)

Zacks, Proactive Investors, OTC Markets, Barchart, Investing.com, TipRanks, Stockwatch, MarketBeat, Journal Transcript, GuruFocus, Trading View, Investors Hangout, Simply Wall St, Macroaxis, Stockopedia, Dividend Investor, The Street, Stockhouse, Wallet Investor, Market Screener, PR Newswire, and Capital Cube reported previously on PASSUR Aerospace, Inc. (PSSR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

PASSUR® Aerospace, Inc.’s mission is to improve international air traffic efficiencies through connecting the world’s aviation professionals onto a single aviation intelligence platform. The Company is a global leader in digital aviation operational excellence. PASSUR provides predictive analytics and decision support technology for the aviation industry, primarily to improve the operational performance and cash flow of airlines and the airports where they operate. Established in 1967, PASSUR Aerospace is headquartered in Stamford, Connecticut and lists on the OTC Markets.

The Company maximizes airspace, runways, and gate usage, by using predictive analytics to determine how airports should be configured to get the most out of their capacity. The Company helps airlines, airports, and air traffic control prioritize departures to maximize capacity and minimize delays, by helping to ensure that all three stakeholders work together with the most accurate, timely information.

PASSUR owns and operates the largest commercial passive radar network worldwide. The Company provides aircraft position updates every 1 to 4.6 seconds, powering a proprietary database that is accessible in real-time, and delivers timely and accurate information and solutions via PASSUR’s industry leading algorithms and business logic included in its products.

The Company’s information solutions are used at the five largest North American airlines, by greater than 60 airport customers. In addition, these information solutions are used at the top 30 North American airports, by more than 100 business aviation customers, and by the U.S. government.

Furthermore, 53 percent of all U.S. domestic commercial flights are managed with PASSUR predictive analytics for predicted arrival times, through using years of archived data, and real-time airspace analysis. This enables airlines and airports to always be ready for the aircraft.

PASSUR Aerospace has its new platform, Ariva™. Ariva represents the complete redesign and relaunch of the PASSUR platform, enabling customers to predict, prevent, and manage disruptions in the air and on the ground. This enables them to be even more proactive because of advanced intelligence.

Last week, PASSUR Aerospace announced that it contracted with the Greater Asheville Regional Airport Authority (GARAA) to provide gate sequencing and airport collaboration solutions on its Ariva™ platform. The design of the Company’s information sharing automated workflow solution is to increase traffic flows and capacity, and decrease delays and congestion, at one of the region's fastest growing airports. GARAA is the sponsor of the Asheville Regional Airport (AVL).

Yesterday, PASSUR Aerospace announced that Mr. Brian Cook, presently a Director of the Company, will assume the additional duties of Chief Executive Officer (CEO). Mr. Cook has served most recently as the CEO and member of the Board of Directors at CyFIR, an innovative cybersecurity software platform and services enterprise.

Mr. Jim Barry, currently President and CEO, will continue with PASSUR as President and member of the Board of Directors. Mr. Barry will concentrate on revenue growth, the development of new products designed to increase on-time performance and lessen block, and providing PASSUR solutions to the aviation industry of problems once thought to be part of the cost of doing business.

PASSUR Aerospace, Inc. (PSSR), closed Wednesday's trading session at $1.00, off by 9.0909%, on 5,100 volume with 3 trades. The average volume for the last 3 months is 1,783 and the stock's 52-week low/high is $0.910000026/$1.70000004.

Pyxus International, Inc. (PYX)

Zacks, Cannabis Market Cap, StockNews, Market Screener, Investing.com, TipRanks, Street Insider, MacroTrends, iWatch Markets, Proactive Investors, Morningstar, InvestorsHub, YCharts, TradingView, GuruFocus, Barchart, Simply Wall St, GlobeNewswire, Stocktwits, and Seeking Alpha reported earlier on Pyxus International, Inc. (PYX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Pyxus International, Inc. operates as an agricultural company. It delivers value-added products and services in leaf tobacco, e-liquids, industrial hemp, as well as legal cannabis industries. The Company has 150 years of farming experience. It has 300,000 global farmer relationships and 30 countries in operation. Pyxus International’s proprietary technology allows each of its products to be traced from seed to sale. Pyxus has its corporate headquarters in Morrisville, North Carolina.

The Company uses industry-leading technology and works with its extensive network of agronomists worldwide. Its products are independently verified to guarantee quality and efficacy. Pyxus uses its proprietary track-and-trace platform, which enables customers to understand the journey of their product from source-to-market.

Pyxus International partners with commercial and smallholder growers to provide resources including seeds, fertilizer, as well as other agricultural materials. The Company’s extensive team of agronomists work with growers globally to help them maximize yields and deliver products to meet customer requirements and consumer demand.

The Company uses the Grower Management System (GMS). GMS is an award-winning data management tool. It amalgamates farmer information related to farm assets, natural resource management, reforestation, farm labor health and quality, crop management, grower sustainability, and training on good agricultural labor practices. The information is subsequently used to develop solutions to compliance issues.

Earlier this month, Pyxus International announced that it and Shenzhen Smoore Technology Co, LTD., a foremost manufacturer of electronic nicotine delivery systems (ENDS), entered into an agreement to share key costs, and also research and testing data, considerably improving efficiencies related to their respective Premarket Tobacco Product Applications (PMTA). All tobacco products introduced or modified after Feb. 15, 2007, require pre-market authorization by the Food and Drug Administration (FDA) in order to be commercially marketed in the USA. Pursuant to FDA guidance, all PMTAs are due by May 12, 2020.

Last week, Pyxus International announced results for its fiscal quarter ended December 31, 2019. Selected highlights include Sales and Other Operating Revenues falling 30.7 percent to $363.3 million versus last year, because of a decrease in volume and average sale prices. The volume decrease was driven by flue-cured oversupply conditions, shipment timing, and the impact of Hurricane Florence and foreign tariffs in the United States. Net Loss Attributable to Pyxus International for the three months ended December 31, 2019 was $22.0 million.

Pyxus International, Inc. (PYX), closed Wednesday's trading session at $4.26, off by 2.069%, on 697,470 volume with 3,355 trades. The average volume for the last 3 months is 482,868 and the stock's 52-week low/high is $4.07000017/$32.6899986.

Sitka Gold Corporation (SITKF)

Gold Chartered, Junior Mining Network, OTC Markets, TeleTrader, Stockwatch, Dividend Investor, Ceo.ca, TradingView, Stockhouse, GuruFocus, FinScreener, Barchart, Wallet Investor, Dividend.com, Canadian Insider, and Market Screener reported beforehand on Sitka Gold Corporation (SITKF), and today we report on the Company, here at the Quality Stocks Daily Newsletter.

Sitka Gold Corporation is a junior explorer targeting gold, silver and copper properties. The Company concentrates on discovery and was formed by the previous founders of Tundra Copper Corp., which was sold in 2014 for a significant return to investors. Sitka’s assets include 4 drill-ready properties with considerable upside potential. The Company has its head office in Vancouver, British Columbia. Sitka Gold lists on the OTC Markets.

The Company has an experienced management team with a track record of past discoveries, mine production, as well as shareholder success. Sitka Gold’s assets include the Burro Creek Gold-Silver Deposit, Arizona; the Alpha Gold Project, Nevada; the RC Gold Project, Yukon; and the Coppermine River Project, Nunavut.

The Burro Creek Gold-Silver Deposit is positioned roughly 200 km northwest of Phoenix, Arizona. It has existing mining infrastructure and is road accessible. Burro Creek is a low sulphidation epithermal gold-silver vein deposit and includes zones of Bonanza grades. The historical 2011 NI-43-101 resource calculation estimates about 5 Moz silver and 120,000 oz gold (Indicated and Inferred).

The Alpha Gold Property is a Carlin-type gold target in the heart of the Carlin District. This District is the second-most prolific gold-producing area in the world. The Alpha Gold Property is a 1,000-acre property with premier infrastructure. It is 100 percent owned by Sitka Gold.

The RC Gold Project is an intrusion-related gold target in the heart of the Tintina Gold Belt, Yukon. Sitka Gold recently acquired a 100 percent interest in the Mahtin Gold Property and has an option to acquire a 100 percent interest in the RC Gold Property. On January 30, 2020 the Company acquired the Mahtin Gold Property expanding the RC Gold Project to greater than 80,000 acres of highly prospective ground with many intrusion related gold targets to drill test.

The Coppermine River Project is a 50,500-hectare (125,000-acre) land package situated near Kugluktuk, Nunavut. This Project is 100 percent owned by Sitka Gold via its subsidiary Arctic Copper Corp. High grade samples from the Coppermine River Project run up to 41.54 percent Cu.

Sitka Gold recently announced that it sent ALS Laboratories the second shipment of drill core for analysis from its continuing diamond drill program at its Burro Creek Gold Property in Arizona. The shipment contains drill core samples from BC20-060 and BC20-061. These are the first step-out holes along a newly constructed road south of the earlier drilled gold and silver mineralization. The holes lie 75m SSE of BC19-057, which was drilled within the Burro Creek historic gold-silver resource area.

Recently, Sitka Gold announced a non-brokered private placement of up to 6 million units at a price of $0.22 per unit for gross proceeds of up to $1,320,000. Each Unit will consist of one common share of the Company and one half of one share purchase warrant. Each whole warrant will entitle the holder to purchase an additional common share at a price of $0.30 for a period of 12 months from the date of closing of the Private Placement. Sitka’s intention is to use the net proceeds of the Private Placement for exploration work on its Arizona, Nevada, and Yukon gold properties and for general working capital.

Sitka Gold Corporation (SITKF), closed Wednesday's trading session at $0.1739, up 0.230548%, on 4,750 volume with 4 trades. The average volume for the last 3 months is 16,162 and the stock's 52-week low/high is $0.095399998/$0.182500004.

Real Goods Solar, Inc. (RGSE)

StockTwits, Zacks, 4-Traders, Investing.com, Insider Tracking, Investors Observer, AIStockFinder, Barchart, GlobeNewswire, Stockhouse, Market Screener, and MacroTrends reported earlier on Real Goods Solar, Inc. (RGSE), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Real Goods Solar, Inc. (RGS Energy) is the exclusive worldwide manufacturer of the POWERHOUSE™ Solar Shingle System. This is an inventive in-roof solar shingle employing technology developed by The Dow Chemical Company. The design of POWERHOUSE solar shingles are to integrate with asphalt roofing products. The POWERHOUSE Solar Shingle is a pioneering new roofing tile product that combines the performance and protection of a conventional asphalt roof with an integrated photovoltaic (PV) system that powers a home. Real Goods Solar has its head office in Denver, Colorado. The Company’s shares trade on the OTC Markets Group’s OTCQX.

RGS Energy (RGSE) is exiting its mainland residential solar business to focus on the POWERHOUSE™ in-roof shingle market. The Company is concentrating its efforts and resources on what it believes is a significant opportunity with its POWERHOUSE™ solar shingle. This is because of the State of California’s mandate that all new homes built in 2020 include a solar installation. POWERHOUSE™ is a trademark of The Dow Chemical Company, used under license.

RGSE believes the POWERHOUSE™ solar shingle has compelling competitive advantages. These include an aesthetically appealing low profile, with power efficiency and cost competitive to traditional rack-n-mount solar.

The POWERHOUSE 3.0 Solar Shingles operate as a roof and solar product. They are installed directly onto the roof deck along with standard asphalt roofing shingles. The design of POWERHOUSE 3.0 is to achieve a competitive price point for Roofers; Homebuilders; Homeowners; as well as Solar Installers.

Recently, RGSE announced that it joined Builder Partnerships network to offer POWERHOUSE™ to their more than 1,400 builder members. Builder Partnerships network is an innovative networking organization. It supports top regional builders and manufacturers as they compete and thrive in today’s competitive environment. Builder Partnerships helps their members generate premier returns, establish strategic relationships, and enhance management practices.

Real Goods Solar, Inc. (RGSE), closed Wednesday's trading session at $0.0083, up 36.0656%, on 7,472,329 volume with 201 trades. The average volume for the last 3 months is 2,184,993 and the stock's 52-week low/high is $0.0051/$0.450100004.

Natural Health Farm Holdings, Inc. (NHEL)

Stockopedia, Stockhouse, Market Exclusive, Capital Cube, 4-Traders, Street Insider, Morningstar, Simply Wall St, InvestorsHub, OTC Markets, GuruFocus, MarketWatch, Last10k, and Barchart reported earlier on Natural Health Farm Holdings, Inc. (NHEL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Natural Health Farm Holdings, Inc. is a biotechnology company working to establish a complete healthcare one-stop shop based on natural or naturopathic products. Since November of 2017, the Company has developed and started to commercialize the web-based Naturopathic Learning Management System to enable consumers and distributors to be educated on health-related aspects of various diseases and nutritional consulting services. Natural Health Farm Holdings is headquartered in Las Vegas, Nevada. The Company lists on the OTCQB.

Natural Health Farm provides online nutritional consultation services. It does so through offering a web-based naturopathic learning management system. This system educates their customers on general wellbeing. The Company’s principal activities are in retailing nutritional supplements, organic foods and health-care related products.

Via its subsidiary, NHF International Limited, Natural Health Farm specializes in biotechnology research & development, and a retail business. It has a chain of numerous retail & franchise outlets throughout Malaysia and other nations. These include Singapore, Brunei, Philippines, China, Hong Kong and the United States.

Natural Health Farm Holdings announced this past January that it executed a term sheet to acquire all of the issued and outstanding shares of Natural Tech R&D Sdn Bhd, a BioNexus accredited research and development company in Malaysia. With the agreement, Natural Health Farm shall acquire 100 percent of Natural Tech R&D’s outstanding shares for USD 1 Million.

Natural Health Farm Holdings also announced in January that it executed a term sheet to acquire all of the issued and outstanding shares of Excel Herbal Industries Sdn Bhd. Excel Herbal is a nutraceutical biotechnology manufacturing, organic food and health supplements business in Malaysia.

Recently, Natural Health Farm Holdings announced that it executed a term sheet to acquire all of the issued and outstanding shares of Natural Health Naturopathic Academy Sdn Bhd (NHNA), a Malaysian healthcare education provider. Natural Health Naturopathic Academy offers courses on health, nutrition, dietetic and Chinese & natural medicine, which are accredited by over 30 countries.

Natural Health Farm Holdings also recently announced that it executed a term sheet to acquire a majority equity interest in Biodelta (Pty) Ltd. Biodelta is a contract developer and manufacturer of nutraceutical products in South Africa. Furthermore, this month, the Company announced that it executed an agreement to acquire all the issued and outstanding shares of Natural Health Farm, Inc. (NHF). NHF is a distributor of naturopathic and nutraceutical products in North Carolina and throughout the East Coast of the United States.

Natural Health Farm Holdings, Inc. (NHEL), closed Wednesday's trading session at $0.02, up 60.00%, on 1,000 volume with 1 trade. The average volume for the last 3 months is 2,640 and the stock's 52-week low/high is $0.000099999/$6.00.

Dakota Territory Resource Corp. (DTRC)

InvestorsHub, Zacks, Market Screener, YCharts, TradingView, Stockhouse, Barchart, Simply Wall St, Uptick Newswire, Real Investment Advice, Innovative Marketing, OTC Markets Group, Ultimate Penny Stock, MarketWatch, The Street, Marketbeat, Dividend Investor, last19k, Wallet Investor, Corporate Information, and 4-Traders reported earlier on Dakota Territory Resource Corp. (DTRC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Dakota Territory Resource Corp.’s emphasis is on the acquisition and responsible exploration and development of high caliber gold properties in the Black Hills of South Dakota. The Company maintains 100 percent ownership of three gold properties encompassing roughly 4,059 acres. These include the Blind Gold, City Creek, and Homestake Paleoplacer Properties. All of these properties are in the heart of the Homestake District. OTCQB-listed, Dakota Territory Resource is headquartered in Reno, Nevada.

The Company’s flagship property is the Blind Gold Property, which is a target for Tertiary-aged and Iron-formation gold mineralization. The Blind Gold Property is about four miles northwest and on structural trend with the historic Homestake Gold Mine.

The Homestake Gold Mine produced roughly 40 million ounces of gold through its 125-year production history. It is the largest iron-formation-hosted gold deposit in the world.

Dakota Territory’s plan is to continue its sampling program along trend of the zone of high grade gold mineralization identified by the first pass surface sampling program conducted on its 100 percent owned Blind Gold Property. The program identified a zone of high-grade gold mineralization in the Mississippian-age Pahasapa Limestone on the surface, with a peak gold assay value of 9.44 grams per tonne.

The Homestake Paleoplacer Property consists of 13 unpatented lode mining claims. These are situated one-mile north of the Homestake Open Cut. Dakota based the acquisition of its Black Hills property position on more than 44 years of combined mining and exploration experience in the Homestake District.

The Company’s City Creek Property is a target for Homestake iron-formation gold mineralization. City Creek consists of 21 unpatented lode mining claims. These are positioned one-mile northeast of the Homestake Open Cut and one-mile northwest of the City of Deadwood.

Recently, Dakota Territory Resource announced the appointment of Mr. Lee Graber to the Company’s Strategic Advisory Committee. Mr. Graber has more than four decades of experience in the mining industry. This includes 23 years with Homestake Mining Company, one of the largest gold mining companies in the U.S. until it was acquired in 2002 by Barrick Gold Corporation.

As Homestake's Vice President responsible for corporate development, Mr. Graber initiated, managed, and closed manifold joint venture agreements, major acquisitions, and divestment transactions. After Homestake, Mr. Graber served as Managing Director, Mergers and Acquisitions, for Endeavour Financial Ltd.

Dakota Territory Resource Corp. (DTRC), closed Wednesday's trading session at $0.20, up 103.0457%, on 450,618 volume with 74 trades. The average volume for the last 3 months is 16,452 and the stock's 52-week low/high is $0.019999999/$0.200000002.

RespireRx Pharmaceuticals, Inc. (RSPI)

NetworkNewsWire, Penny Stock Tweets, Infront Analytics, Stockflare, Barchart, InvestorsHub, Stockopedia, Penny Stock Hub, Wallet Investor, Simply Wall St, Marketbeat, YCharts, Street Insider, Marketwired, Stockhouse, Daily Marijuana Observer, last10k, Investors Hangout, GuruFocus, MarketWatch, Stockwatch, 4-Traders, and Real Investment Advice reported earlier on RespireRx Pharmaceuticals, Inc. (RSPI), and today we report on the Company, here at the QualityStocks Daily Newsletter.

RespireRx Pharmaceuticals, Inc. is a leader in the development of medicines for respiratory disorders and CNS indications, with a concentration on obstructive sleep apnea, attention deficit hyperactivity disorder (ADHD), spinal cord injury, other neurological conditions and drug-induced respiratory depression. RespireRx Pharmaceuticals has its corporate office in Glen Rock, New Jersey. The Company lists on the OTC Markets Group’s OTCQB.

RespireRx has filed over 400 patents in the U.S. and offshore that claim composition of matter, use, formulation, dosage, as well as mechanism of action. Use claims include treating sleep apnea and preventing or rescuing drug-induced respiratory depression, and also for improving memory and cognition, treating schizophrenia and other central nervous system (CNS) indications.    

The Company’s pharmaceutical candidates in development are derived from two platforms. One platform is the class of compounds called cannabinoids. This includes, in particular, Dronabinol. Dronabinol (D9-THC, D9-tetrahydrocannabinol) is an oral capsule drug product. Dronabinol (D9-THC) is a generic, orally active cannabinoid. It is undergoing testing for clinical efficacy in patients with obstructive sleep apnea (OSA).

RespireRx Pharmaceuticals (under a license agreement with the University of Illinois) has rights to patents claiming the use of cannabinoids for the treatment of sleep-related breathing disorders. Two Phase 2 clinical trials have been completed. Both have demonstrated substantial reductions in sleep apnea produced by dronabinol. 

Dronabinol is Food and Drug Administration (FDA) approved for the treatment of anorexia in AIDS patients and nausea and vomiting in cancer patients undergoing chemotherapy (Marinol®). It is a Schedule III drug available by prescription, with a low risk of addiction.

The other platform of medicines undergoing development by RespireRx is a class of proprietary compounds called ampakines. These act to enhance the actions of the excitatory neurotransmitter glutamate at AMPA glutamate receptor sites in the brain. Several ampakines, in oral and injectable form, are undergoing development by RespireRx for the treatment of an assortment of breathing disorders.

Recently, RespireRx Pharmaceuticals announcd the promotion of Mr. James Sapirstein to Executive Vice Chairman of the Board of Directors effective December 28, 2018. Mr. Sapirstein has served as a member of the Board of Directors since 2014. He expands his role within RespireRx Pharmaceuticals to assist with business development and fundraising activities to advance the development of the Company’s pipeline of neuromodulators with an emphasis on sleep apnea and neurologic and psychiatric disorders.

Mr. Sapirstein is a highly-regarded pharmaceutical industry executive. He has more than 35 years of success in building companies and leading the commercial launch of almost two dozen prescription drugs in the fields of CNS, infectious disease, and cancer. Mr. Sapirstein has worked at major pharmaceutical companies, Bristol-Myers Squibb, Hoffmann-LaRoche and Eli Lilly. He has also led commercial teams for biotechnology companies including Gilead Sciences and Serono Laboratories.

RespireRx Pharmaceuticals, Inc. (RSPI), closed Wednesday's trading session at $0.115, up 35.2941%, on 138,216 volume with 10 trades. The average volume for the last 3 months is 14,670 and the stock's 52-week low/high is $0.071000002/$0.850000023.

StartMonday Technology Corp. (STMDF)

Dividend Investor, OTC Markets, Stockhouse, MarketWatch, Barchart, GuruFocus, Science of Stocks, Investorx.ca, and Penny Stock Hub reported on StartMonday Technology Corp. (STMDF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

StartMonday Technology Corp. engages in candidate selection solutions for employers in the retail and hospitality sectors. The Company helps employers choose better candidates, quicker, with the power of 15-second video introductions. A smart recruitment technology enterprise, StartMonday Technology has its corporate headquarters in Vancouver, British Columbia. The Company’s shares trade on the OTC Markets Group’s OTCQB.

StartMonday Technology was founded by professionals from the recruiting and tech fields - Ray Gibson from recruiting and HR, and Andrew Evans from the founding team at Careerbuilder.com.

StartMonday Technology’s commitment is to building strong tools for the Mobile Generation. Moreover, the Company is further developing its technology with an open blockchain solution for verifiable career histories named CareerChain.

StartMonday's video-led mobile and web applications deliver a better impression of customer skills and personality, ultimately assisting employers in deciding which candidates they should talk to first. This makes the process much more efficient.

StartMonday's core products center around 15-second videos filmed by candidates on their own mobile phones and web browsers. This puts job applications decisively in the social media and mobile native arena.

This enables job seekers to present themselves in their own way. In addition to lessening cost and time-to-hire, the Company brings massive employer branding opportunities to its clients.

Recently, StartMonday Technology announced that it has partnered with Talent Tech Labs (TTL)- Manhattan-based, as part of their late-stage accelerator program targeted at advancing select, mature startups ready for targeted penetration into the North American market. Talent Tech Labs is a sector leader in the knowledge and analysis of up-and-coming trends and technologies applied to improving the state of the art of recruitment.

StartMonday Co-Founder and Chief Executive Officer, Mr. Ray Gibson said, “We are extremely pleased to have been selected for the TTL accelerator program. This is a limited and very influential opportunity that has previously proven its worth at propelling entry into the U.S. marketplace… We believe this program will ideally position us to really show what StartMonday and CareerChain can do to accelerate success within the HR industry arm of Corporate America.”

StartMonday Technology Corp. (STMDF), closed Wednesday's trading session at $0.01525, up 174.7748%, on 600 volume with 1 trade. The average volume for the last 3 months is 1,977 and the stock's 52-week low/high is $0.003599999/$0.100000001.

Sunset Island Group, Inc. (SIGO)

MicrocapVoice, PennyStockSpy,  OTCPicks,  and 007 Stock Chat reported earlier on Sunset Island Group, Inc. (SIGO), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Sunset Island Group, Inc. provides consulting and advisory services to clients operating in the medical marijuana business space.  The Company concentrates on providing a licensed manufacturing facility to clients for producing products, including oils and edibles. Sunset Island Group has its corporate office in San Clemente,  California.

The Company’s vision is to establish a fully integrated business, which provides turnkey solutions to the medical cannabis industry. Its primary emphasis is on providing a licensed facility where companies can manufacture and produce their products. In addition, Sunset Island will provide distribution for companies via an established network of dispensaries.

Sunset Island Group earlier secured a lease on a property approved for cannabis cultivation. The Company for permits for 22,000 square feet of green house space. The expectation is that the 22,000 square feet of green house space will be able to produce up to 4,000 pounds of medical cannabis each year. 

Sunset Island announced last year that it initiated development of a CBD dietary supplement product. The initial product will feature a 2-oz stress relief beverage made from highest quality legal Hemp/CBD oil and real fruit.

Sunset Island will continue to develop products that will address the demands in the worldwide dietary supplements market. This market is targeted to soon reach greater than $200 billion.  The product will undergo development by a trained French Chef with more than two decades of experience in Product Development and Food Production.

Sunset Island Group is performing a retrofit to its current grow space that will considerably increase the amount of cannabis product produced with each harvest. Furthermore, the Company announced in November 2017 that it commenced an aggressive expansion of its cannabis product line.

The Company’s retro fit is two phases. Phase 1 is the retro fit of the present greenhouse operations. Phase 2 is the constructing of a new greenhouse on its bare land or retrofitting another greenhouse on the property.

The aim of the retro fit for Phase 1 is to increase the growable space in the current greenhouse to about 22,000 (with a vertical grow) with roughly 85 percent being canopy space (or around 19,000 square feet). The Company's objective is to yield 0.08-0.10 pounds per growable space and to have five harvests.

Sunset Island Group has received its temporary licenses from the State of California for Distribution, Cultivation and Manufacturing. The licenses are for Adult Use (Recreational) and Medicinal. The licenses permit Sunset Island to sell and transport its own product to dispensaries across California.

The manufacturing license allows it to start manufacturing products such as vape cartridges, edibles, as well as extracts. At present, Sunset Island is in the process of converting one of its cold storage rooms into a clean room to commence manufacturing these products.

Sunset Island Group, Inc. (SIGO), closed Wednesday's trading session at $0.05, up 42.8571%, on 2,000 volume with 1 trade. The average volume for the last 3 months is 2,542 and the stock's 52-week low/high is $0.029999999/$0.323500007.

Continental Energy Corp. (CPPXF)

TopPennyStockMovers, Streetwise Reports, and Agoracom reported previously on Continental Energy Corp. (CPPXF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Continental Energy Corp. is an emerging developer of conventional and alternative energy capacity integrated with upstream and downstream petroleum supply within the Republic of Indonesia. Listed on the OTC Markets, the Company’s commitment is to developing hybrid renewable electrical power generation capacity and profitably operating mini-grid distribution networks in the huge, under-served markets of the fast-growing economies encircling the Indian Ocean Rim.

Established in 1984, Continental Energy is headquartered in Vancouver, British Columbia. The Company previously went by the name Continental Copper Corp. It changed its corporate name to Continental Energy Corp. in October of 1997.

The Company’s core competency exists in Indonesia. It has 30 years of experience in Indonesia. This has given Continental Energy the business relationships and local operating experience necessary to capitalize on the rising energy demand in this country.

In addition, Continental Energy has its business combination with the Ruaha River Power Company. This business combination provided instant entry into Tanzania. This is where the best-in-Africa commercial incentives for small scale renewable energy developers are in place to foster new supply of power to off-grid communities.

Continental Energy Corp. (CPPXF), closed Wednesday's trading session at $0.02, up 33.3333%, on 850 volume with 1 trade. The average volume for the last 3 months is 28,365 and the stock's 52-week low/high is $0.0026/$0.029999999.

The QualityStocks Company Corner

Trxade Group Inc. (NASDAQ: MEDS)

The QualityStocks Daily Newsletter would like to spotlight Trxade Group Inc. (NASDAQ: MEDS).

Trxade Group Inc. (NASDAQ: MEDS), an integrated drug delivery, procurement, and healthcare platform that offers healthcare buyers and sellers of pharmaceuticals increased profit margins, announced that its common stock has begun trading on the Nasdaq Capital Market under new ticker symbol ‘MEDS’, as of February 13, 2020. The company’s common stock will cease trading on the OTCQB. Also today, NetworkNewsWire released a report on the company detailing how, on Tuesday announced the closing of its underwritten public offering of 806,452 shares of common stock at a price to the public of $6.50 each. To view the full press release, visit http://nnw.fm/w0gsH

Trxade Group Inc. (NASDAQ: MEDS) is an integrated pharmaceutical services company that offers a unique combination of a web-based purchasing platform (www.trxade.com) for transactions between independent pharmacists and drug distributors (B2B); a network of pharmacies with E-Hub software; a mail order pharmacy; and warehouse and drug delivery services. This synergistic combination of product offerings and superior data analytics is poised to benefit all stakeholders and consumers within the pharmaceutical industry.

Trxade will leverage and scale its fully integrated model to execute the following growth strategies:

  • Increase share of pharmacist drug purchasing
  • Additional SKUs and expand product breath
  • Partner with Specialty and International Mfg.
  • Expand mail order licenses to all 50 states
  • Scale Delivmeds for consumer delivery nationwide
  • Integration with telemedicine
  • M&A Opportunities within drug value chain

Founded in 2010 and headquartered in Tampa, Florida, Trxade’s overarching corporate strategy is to penetrate the existing retail independent pharmacy marketplace and diversify the company’s pharmaceutical mix with additional specialty and acute care products. Trxade is advancing on this mission by focusing on three key niches in the health care market.

Business-to-Business (B2B)

The $330 billion U.S. pharmaceutical industry is comprised of more than 65,000 pharmacy facilities and 1,500 state-licensed suppliers. Roughly 24,000 of these facilities are independent pharmacies, which collectively spend approximately $93 billion a year on branded and generic drugs.

Trxade targets these independent pharmacies, leveraging a robust, “E-Bay/Kayak-like” technology platform with optimum buyer/seller pricing algorithms, product availability, and predictive data analytics features.

Trxade currently serves and transacts with more than one-third (10,250) of these independent pharmacies and facilitates over $10 million of drug purchases a month!

Consumer

Trxade also targets the “consumer side” of the pharmaceutical industry, aiming to lower prescription drug costs by attacking the inefficient value chain; offering drug price transparency and efficient buying; and, delivering drugs DIRECT to independent pharmacists and consumers.

The company operates a full-service mail order pharmacy for U.S. consumers, as well as a mobile app called “Delivmeds” (http://www.delivmeds.com) which enables SAME DAY home delivery of dispensed prescriptions.

Retail

Trxade’s Managed Services Organization (“TrxadeMSO”) enables its member independent retail pharmacies to get patients, process orders, and deliver or ship prescriptions to patients. TrxadeMSO provides access to encompassing network of pharmacies through the E-Hub software, allowing for timely and comprehensive medication fulfillment.

These offerings ensure the best-suited pharmacy receives the patient’s information, thereby ensuring appropriate medication coverage based on the patient’s location, payor coverage, and medication access/inventory. This will save the clinicians and their staff time as they benefit from efficiency and enhanced workflow management in script processing and fulfillment.

Health Care Market

The U.S. health care market currently hovers near $4 trillion and is expected to grow as the general population ages. This growth will have greater impact on consumers as out-of-pocket expenses also rise. Additionally, drug costs are paced to increase faster than the overall health care and well above inflation.

Drug pricing is variable, and reimbursement is squeezing profits. This provides significant opportunity for the Trxade model of price visibility and profit optimization.

Trxade’s fair online market platform targets the nation’s retail community and independent pharmacies, of which there are approximately 24,000 nationwide. TRxADE has found that independent pharmacies, in order to be cost-effective, often operate with minimal staff and conduct up-to-the minute price checks. The TRxADE S2P platform gives these pharmacists the ability to easily compare the price of drugs offered by various suppliers and select the most favorable deals, saving money by taking advantage of best purchase pricing.

TRxADE’s programs include:

  • TRxADE Exchange, which opens and widens the distribution channel to the retail, community pharmacy. A purchasing pharmacy can view products from manufacturers, buying groups, and wholesalers on a real-time and continuous basis. This approach significantly enhances the competitive spirit of the exchange where the lowest price exists for each product at any given point in time. TRxADE has become a competitive tool for all progressive entities and is recognized for its easy searching of hard-to-find generic pharmaceuticals at substantially reduced prices.  
  • RX Guru™ is an industry-leading price prediction model that integrates product shortage insight into pharmacy acquisition benchmarks (“PAC”) to ascertain trends and pricing variances that result in significant purchasing opportunities. RX Guru affords members the opportunity to continuously benefit from real price purchasing opportunities that are concealed from the rest of the industry. 
  • Product Shortage Database – TRxADE maintains the most comprehensive retail, specialty and acute care pharmaceutical product shortage database in the country. Other industry competitors mainly restrict their efforts to specialty and acute care product shortages and narrowly research oral generic products. TRxADE’s advanced prediction tools help members source those hard-to-find products at affordable costs in a timely and easy-to-search process. 

Management Team 

Trxade’s management team is rich in expertise within the pharmaceutical supply chain and is supported by a base of advisors and contractors who are experts in related fields of the pharmaceutical sector.

Suren Ajjarapu – Chairman of the Board, Chief Executive Officer and Secretary
Suren Ajjarapu has served as Trxade’s chairman of the board, CEO and secretary since 2014, and as the chairman of the board, chief executive officer and secretary of Trxade Nevada since its inception. Ajjarapu also serves as a chairman of the board for Feeder Creek Group Inc., since March 2018. Ajjarapu formerly was a founder, CEO and chairman of Sansur Renewable Energy Inc., a company involved in developing wind power sites in the Midwest, United States; a founder, president and director of Aemetis Inc., a biofuels company (AMTX.OB); a founder, chairman and CEO of International Biofuels, a subsidiary of Aemetis Inc.; and a co-founder, COO, and director at Global Information Technology Inc., an IT outsourcing and systems design company. Ajjarapu holds an M.S. in environmental engineering from South Dakota State University, Brookings, South Dakota, and an MBA from the University of South Florida, specializing in international finance and management. Ajjarapu is also a graduate of the Venture Capital and Private Equity program at Harvard University.

Prashant Patel – Director, President and Chief Operating Officer
Prashant Patel has served as Trxade’s full-time president and COO, and as a director since the company’s acquisition of Trxade Nevada in 2014, and as the COO and president and as a director of Trxade Nevada since its inception. He has been a president and member of the board of Trxade since August 2010. Patel is a registered pharmacist and pharmaceutical consultant with over 10 years of experience in retail pharmacy and pharmaceutical logistics. He is the founder of several pharmacies in the Tampa Bay area, in Florida. Since 2008, Patel has been managing member of the APAA LLC pharmacy. Since 2007, Patel has been a vice president of Holiday Pharmacy Inc. Patel graduated from Nottingham University School of Pharmacy and practiced in the United Kingdom before obtaining his masters in Transport, Trade and Finance from Cass Business School, City University, UK.

Trxade Group Inc. (MEDS), closed Wednesday's trading session at $7.773, up 16.0149%, on 41,208 volume with 323 trades. The average volume for the last 3 months is 182,233 and the stock's 52-week low/high is $2.0999999/$10.5600004.

Recent News

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX (NASDAQ: SRAX)founder and CEO Christopher Miglino recently discussed how the company’s proprietary BIGtoken platform has transformed consumer data collection during an exclusive interview at the LD Micro Main Event 2019. To view the full article, visit http://nnw.fm/XN29p. In an exclusive interview with NNW’s Stuart Smith, SRAX Inc. (NASDAQ: SRAX) CEO Chris Miglino discusses the company’s milestone achievements in 2019 as well as its ambitious plans for 2020 to harness the brand recognition built on the emerging regulation underpinning consumer data protection (http://nnw.fm/9JOi4).

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Wednesday's trading session at $2.64, up 5.60%, on 31,803 volume with 130 trades. The average volume for the last 3 months is 101,816 and the stock's 52-week low/high is $1.04999995/$5.8499999.

Recent News

Pacific Rim Cobalt Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE)

The QualityStocks Daily Newsletter would like to spotlight Pacific Rim Cobalt Corp. (OTCQB: PCRCF).

NetworkNewsWire Editorial Coverage: Demand for electric vehicle batteries is pushing up production of nickel, especially in Indonesia, where the government is moving to benefit from its natural resources. One of the companies on the leading edge of this upward momentum is Pacific Rim Cobalt Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE) (PCRCF Profile), which is setting out a bold expansion plan following a successful exploration and development season in Indonesia last year.

Pacific Rim Cobalt Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE) is a Canada-based exploration company focused on the acquisition and development of production-grade battery metals deposits within the Asia-Pacific region, employing a vertically integrated “minerals-to-market” strategy to leverage these assets to their fullest.

Pacific Rim Cobalt Corp. is advancing its flagship, 100% controlled Cyclops Nickel-Cobalt located in Papua Province, Indonesia with a mandate to become a key contributor to Asia-Pacific’s rapidly expanding electric vehicle and battery supply chain.

The Cyclops project, uniquely positioned within the world’s largest producer of nickel and in proximity to China, the world’s largest “Gigafactory”, features near surface, strong nickel-cobalt mineralization. The property is situated in an area with excellent infrastructure including a nearby workforce, supplies, sealed roads, ocean access, nearby port facility and gentle topography. The project area, nestled on the north coast of Papua, Indonesia, establishes Pacific Rim Cobalt well within the economically attractive ocean-going transportation range to Asia and its lucrative, growing industrial markets.

Global demand for renewable power is fueling a massive shift from traditional energy supply chain economics to nickel-reliant lithium-ion batteries, the world’s most widely used power source for portable applications such as electric vehicles and other high-tech applications.

Indonesia has recently approved environmental impact studies for factories to produce battery-grade nickel chemicals in Morowali. The approval will allow investors, such as China’s stainless steel giant Tsingshan Group, to continue the construction of their high-pressure acid leaching plants in Morowali, Central Sulawesi.

Ranjeet Sundher, chief executive officer of Pacific Rim Cobalt, said: “Indonesia continues to make significant strategic decisions, and this latest announcement represents an important step in Pacific Rim Cobalt’s efforts to benefit from Indonesia’s rapid development as a leading market for all stages of the EV supply chain. With offices in Vancouver, Shanghai and Jakarta, Pacific Rim Cobalt is well positioned to leverage Asia’s global dominance in the battery manufacturing sector.”

Indonesia’s commitment extends to the very top of government, with Joko Widodo – Indonesia’s President – stating in September 2019 that “for nickel, we want raw materials to be processed in Indonesia. We want added values”. This supports previous pronouncements from key officials, including Indonesian Maritime Minister, Luhut Pandjaitan who remarked that Indonesia will “become the main player in lithium batteries” and that it will “control the world market”.

The country, which is the world’s top nickel ore exporter, has stopped export of unprocessed nickel ore to support this plan.

During 2019 the Company carried out an extensive exploration and development program on Cyclops and achieved successful nickel results with its drilling and bench-scale scoping tests for processing of materials.

Drilling identified significant horizons of nickel mineralization and bench-scale scoping tests returned positive results for processing of this nickel rich material.

The recovery percentages form the bench-scale test program are set out below (for further information, please refer to the Company’s press release of October 28, 2019):

Sample Nickel (%) Cobalt (%) Iron (%)
Limonite 99.26 98.82 97.77
Low Iron Transition 99.75 97.03 99.22
Saprolite 99.77 >99.9 99.74

 

Selected elevated nickel drill results are provided below from the Company’s shallow drilling program (for further information, please refer to the Company’s press releases of March 5, April 1, April 23, June 13, June 20 and September 10, 2019):

Intersection length (metres from surface) Nickel (%) Cobalt (%)
7.0 2.15% 0.03%
4.0 1.96% 0.04%
2.0 2.00% 0.01%
2.0 1.91% 0.05%

 

2020 will see continued and consistent development in Pacific Rim Cobalt’s strategy as the company continues to set ambitious milestones with the goal of becoming a leading international player in the EV battery metal sector and creating significant long-term shareholder value.

This includes preparations to commission and operate the company’s pilot plant in Canada, which will contain an integrated circuit to produce high-purity nickel and cobalt strip solutions to develop battery-grade nickel and cobalt.

The results of the pilot plant will then be used to establish the design criteria for the subsequent demonstration plant in Indonesia, which will produce nickel and cobalt products suitable to meet market specifications. As well as demonstrating Pacific Rim Cobalt’s ability to produce a product within market specifications, this will also be used to establish the design criteria for the company’s commercial-scale plant.

Pacific Rim Cobalt’s world-class management team includes Ranjeet Sundher, who has over 20 years of capital markets experience. Sundher is also president of Canrim Ventures Ltd., a Singaporean advisory firm specializing in early stage project finance and structure. He previously founded Indogold Exploration, a Jakarta-based mining service firm, and has raised over $40 million for companies in which he was a founder/partner.

Chief Financial Officer Steve Vanry has 25 years of professional experience in senior management positions with public and private natural resources companies, providing expertise in capital markets corporate finance, mergers and acquisitions, regulatory compliance, accounting and financial reporting.

Andre Talaska serves as country manager and technical supervisor. He has over 30 years of experience in the mining and exploration industry and has held senior positions with several companies in Australia and southeast Asia. Shakir Juffry, business development/engineering, is a chemical engineer and extractive metallurgist by background training who has over 20 years of experience in the Indonesian mining and minerals exploration field. Toto Suarto Sajali, operation and development manager, is a mining engineer with over 15 years of experience in Indonesian project assessment, development and operations.

Pacific Rim Cobalt Corp. (OTCQB: PCRCF), closed Wednesday's trading session at $0.2309, up 0.282302%, on 164,240 volume with 71 trades. The average volume for the last 3 months is 21,825 and the stock's 52-week low/high is $0.079999998/$0.259299993.

Recent News

Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF)

The QualityStocks Daily Newsletter would like to spotlight Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF).

Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF) was featured today in the 420 with CNW by CannabisNewsWire. A new study has found that the majority of young adults do not comprehend the levels of tetrahydrocannabinol (THC) in the advertised marijuana edibles. However, researchers have suggested a new manner of communicating the concentration of THC as well as other information on the product labels.

Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF) is a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates. The company’s cannabidiol (“CBD”) yeast-based biosynthesis program produces a high yield, ultrapure, low-cost and scalable manufacturing solution for pharmaceutical, food, beverage and personal care consumers of CBD.

The company is headquartered in Calgary, Alberta, Canada.

Biosynthesis Platform

Willow’s proprietary yeast-based lab strains produce CBD, tetrahydrocannabinol (“THC”), and cannabigerol (“CBG”), as well as certain minor and novel cannabinoids.

The company’s expertise in the esoteric field of biosynthesis and in delivering commercial fermentation pathways for the production of pharmaceutical-grade compounds grew from its origins in opiate research. Willow recently delivered a de novo biosynthesis pathway in yeast for thebaine, a key precursor API used as a feedstock in the manufacture of semi-synthetic opiates such as naloxone (used to reverse opioid overdose) and several common analgesics. Led by Chief Scientific Officer Dr. Peter Facchini, Willow’s research team discovered and patented numerous previously unknown genes coding for core catalytic pathway enzymes, as well as a number of additional non-pathway, yet commercially-essential, accessory genes.

Utilizing this proven synthetic biology platform, Willow’s research team has already begun producing cannabinoids at lab scale, using yeast as the host cell “factory.” This biosynthetic fermentation-based process is capable of producing pharmaceutical grade CBD in 10 days – far less time than traditional plant-based extraction methods.

Willow anticipates its technology can be scaled to produce hundreds of kilograms per batch of cannabinoid API at less than $1,000 per kilogram, thus costing approximately 60% less than current chemical synthesis methods and 90% less than conventional plant-based extraction methods.

World-Class Collaboration

Willow and Noramco Inc., the world’s largest producer of high-quality synthetic cannabinoid APIs and other controlled substance APIs for the pharmaceutical and healthcare industry, have an exclusive, worldwide Joint Development Agreement (“JDA”) to design a yeast-based biosynthesis platform for the production and distribution of a highly pure CBD isolate.

The mutually exclusive agreement calls for Willow to be responsible for optimizing yeast strains in a biosynthetic process to generate ultrapure CBD at high yield and substantially lower cost compared to current methods. Noramco will leverage its decades of experience in producing and delivering CBD and pharmaceutical APIs by being responsible for the scale-up, regulatory submission, marketing and distribution of products manufactured under the JDA.

Each company will invest comparable funds, will retain the intellectual property associated with their respective scopes of work and share equally in gross profits from sales of products manufactured under the JDA.

Market Opportunity

The agreement with Noramco (http://nnw.fm/Mz1vW) addresses the increasing demand for CBD-based APIs and other CBD-infused products by pharmaceutical, nutraceutical, consumer packaged goods, beverages and other industry sectors.

The U.S. market potential of cannabinoids is significant, with industry analysts projecting $50 billion in cannabinoid-based pharmaceutical sales and $16 billion in CBD consumer goods retail sales by 2025. As of June 2019, 34 U.S. states and the District of Columbia, Guam, Puerto Rico and U.S. Virgin Islands have legalized cannabis for medical use. Another 13 states and territories have approved recreational cannabis for adult use while other states are considering similar measures.

The cannabinoid API market continues to evolve with CBD and other cannabinoid-based treatment options currently in clinical trials for indications such as post-traumatic stress syndrome, epilepsy, Parkinson’s disease, chronic pain, schizophrenia, cancer treatments and other challenging unmet medical conditions.

Capitalization

Willow is fully funded after raising $29 million via private placement and $8 million in exercised warrants by Tuatara Capital Fund II, L.P. Proceeds of the funding will be used to enhance the existing laboratory space in Calgary and Vancouver, Canada, and in San Francisco, California. The company anticipates exiting 2020 with $15.8 million in cash.

Leadership

President and CEO Trevor Peters is an experienced executive who co-founded four startup companies in the past 15 years. He has raised over $1 billion in equity and debt financings at various stages of corporate development and has been integral to successful transactions totaling over $4 billion on sale. Mr. Peters previously was chief financial officer at Caracal Energy Inc., which sold to Glencore plc in 2014 for $1.8 billion.

Chief Financial Officer Travis Doupe has over 18 years of experience in financial leadership roles, principally in the international oil and gas industry, where he provided corporate strategic direction while overseeing all aspects of financial operations. Mr. Doupe is the treasurer and a member of the board of directors of the Canada Council for the Americas – Alberta and holds a CA-CPA designation and earned a bachelor’s degree in management from the University of Calgary.

Dr. Peter Facchini, Chief Scientific Officer, has been professor of plant biochemistry in the Department of Biological Sciences at the University of Calgary since 1995. He is recognized internationally as a leader in plant specialized metabolite biosynthesis. Dr. Facchini is the Canada Research Chair in Plant Metabolic Processes Biotechnology and has published more than 150 research papers and scholarly articles. Dr. Facchini received a PhD from the University of Toronto and conducted postdoctoral research at the University of Kentucky and Université de Montréal.

Dr. Joseph Tucker, Executive Chairman of the Board of Directors, holds more than 20 issued or pending patents and is a member of the Board of Directors of BioAlberta. He has extensive senior leadership experience in multiple public and private biotech companies. Dr. Tucker received a PhD in biochemistry and molecular biology from the University of Calgary.

Willow Biosciences Inc. (OTCQB: CANSF), closed Wednesday's trading session at $0.532, even for the day, on 450 volume. The average volume for the last 3 months is 8,920 and the stock's 52-week low/high is $0.400999993/$2.1775.

Recent News

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

TumorGenesis, a flagship subsidiary of Predictive Oncology Inc. (NASDAQ: POAI), has made concrete steps in identifying and separating cancer-related biomarkers, which is likely to speed the development of new and effective therapeutics. TumorGenesis media are specially formulated to help researchers isolate and maintain the unique histological and basic biological signatures of ovarian cell types while growing them in the laboratory. This breakthrough approach is likely to help POAI become a frontrunner in providing the needed tools for personalized medicine and new drug development, which carries important implications for the company’s future valuation.

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

  • A database of clinically validated historical and outcome data from patient tumors
  • An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
  • A “smart” patient-derived tumor profiling platform
  • An in-house bioinformatics artificial intelligence (AI) platform
  • A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
  • An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Wednesday's trading session at $2.34, off by 3.3058%, on 50,818 volume with 213 trades. The average volume for the last 3 months is 135,600 and the stock's 52-week low/high is $2.28999996/$8.50.

Recent News

MCTC Holdings Inc. (OTC: MCTC)

The QualityStocks Daily Newsletter would like to spotlight MCTC Holdings Inc. (MCTC).

MCTC Holdings Inc. (OTC: MCTC) was featured today in a publication from HempWireNews, examining how scientists have discovered that since the legalization of industrial hemp took place in 2018 under the Department of Agriculture Farm Bill, the newly green fields of Cannabis Sativa L. have had unexpected benefits upon the bee population as it is helping boost their numbers.

MCTC Holdings Inc. (OTC: MCTC) is an innovator in the field of cannabinoid nanoparticles and infusion technologies with several important cannabinoid patents filed and an active research and development program underway. The company was reorganized during June of 2019 and announced its intent to enter the cannabis sector and change its corporate identity to Cannabis Global Inc. The company is headquartered in Los Angeles, California.

With the hemp and cannabis industries rapidly expanding in terms of market size, acceptance and number of market participants, MCTC plans to concentrate its efforts on the middle portions of the hemp and cannabis value chain. The company is actively pursuing R&D programs and productization of advanced cannabinoid delivery systems, based on solid polymeric nanoparticles and fibers. These technologies hold the promise to revolutionize the science of cannabinoid bio-enhancement for use in foods, beverages, consumer products and in transdermal applications. Because of nanoparticles’ ability to be quickly absorbed into the bloodstream, nanotechnology has been utilized in the food and drug industry for some time and has the potential for tremendous growth in the cannabis industry (http://nnw.fm/v6RQ6).

Cutting-Edge Technology

MCTC is at the cutting-edge of the cannabis industry’s trends with its emphasis on polymeric nanotechnology. This is not to be confused with the more basic oil-in-water nano-emulsions currently marketed to the food and beverage industry. The company’s polymer-based particles offer significant loading of active ingredients and unmatched flexibility and customization, allowing for myriad combinations of cannabinoids with unique performance characteristics. MCTC believes polymeric nanotechnology particles will be a critical technology area for the cannabinoid formulation marketplace.

The company continues to build its R&D program, specifically researching the development of improving methods to make cannabinoids available to living systems. Instrumental in the research program is the development of novel polymeric nanoparticles and nanofibers. These have the potential to elevate the potential of cannabinoid products in the following ways (http://nnw.fm/cK3Bl):

  • Significantly improving bioavailability
  • Allowing for ultra-high loading rates
  • Enhancing customization of cannabinoid combinations
  • Improved dosing precision
  • Providing more control in release parameters

MCTC leadership understands the importance of developing intellectual property (IP) in the ever-evolving cannabis industry. A recent Forbes article described IP as “critical for creating true differentiation between companies and their product and service offerings” (http://nnw.fm/57Fjh). Recognizing the importance of IP, MCTC has been consistent in its application for patents to protect its innovative nanotechnology applications.

Patents

MCTC has now filed four patents on its cannabinoid delivery technology systems:

  • The company first collaborated with Cannabis Nanosciences Inc. on technologies. This became the basis for its first patent filing on an innovative edible dissolvable film for cannabinoid ingestion.
  • Its second patent filing for cannabinoid nanoparticles combined TPGS, a water-soluble form of vitamin E.
  • Its third patent filing involved a unique 4th dimension, 3D printed cannabinoid delivery system for beverages.
  • Its fourth patent, considered its most significant, broadly covers many aspects of nanoparticles and nano fibers comprising one or more cannabinoids disposed at least partially within a water-soluble medium.

Collaborations

MCTC collaborated with Marijuana Company Inc. (OTCQB: MCOA) subsidiary hempSmart Inc., under a hemp extract and CBD product supply agreement wherein hempSmart will utilize its extensive network of marketing partners to market MCTC’s powered drink mixes and other CBD edibles online. These products are designed for the dry beverage and edibles sector and will be supplied by MCTC. They incorporate the company’s patent-pending cannabinoid infusion technologies and will be trademarked as Hemp You Can Feel (TM) and Gummies You Can Feel (TM).

Leadership

MCTC CEO and chairman Arman Tabatabaei boasts 15 years of management and operations experience and is considered an expert at data collection and analysis relative to resource management, risk forecasting, and profit and loss management. He has acted as a consultant with Cannabis Strategic Ventures (OTCQB: NUGS) and played an instrumental role in improving operations at Sugarmade Inc. (OTCQB: SGMD) relative to the company’s hydroponic growth supplies initiatives.

MCTC founder and director Robert Hymers also brings a seasoned perspective, having had significant experiences in the cannabis industry and as a financial executive and consultant. He is the managing partner of Pinnacle Tax Services in Los Angeles and was previously CFO and director of Marijuana Company of America Inc. (OTC: MCOA). He is currently a member of the Strategic Advisory Board at Massroots Inc. and acts as a consultant to both Cannabis Strategic Ventures Inc. and Sugarmade Inc. Hymers’ background in tax accounting, auditing, SEC reporting, mergers and acquisitions, and corporate finance has immense value in his current position at MCTC Holdings.

MCTC Holdings Inc. (MCTC), closed Wednesday's trading session at $0.26875, off by 7.3276%, on 6,706 volume with 7 trades. The average volume for the last 3 months is 18,452 and the stock's 52-week low/high is $0.090000003/$3.00.

Recent News

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services Global Corporation (OTCQB: SHRG) is a holding company that owns, operates or controls an interest in companies specializing in the direct-selling industry. The company’s emphasis is on direct selling, and SHRG has grown by thousands of independent sales representatives over the past year. Through one of its strategic avenues to help empower its growing body of Elepreneurs, the company recently announced its 2020 Happiness Conference, slated to take place April 16-19 in Grapevine, Texas.

Sharing Services Global Corporation (SHRG), formerly Sharing Services Inc., is a diversified company dedicated to maximizing shareholder value, operating through two primary subsidiaries: Elepreneurs Holdings, a direct-selling company, and Elevacity Holdings, a products company. Headquartered in Plano, Texas, SHRG markets and distributes Elevate-branded health and wellness products through an independent sales force of distributors called Elepreneurs.

Proprietary Products

SHRG’s current exclusive Elevate product offerings are marketed under the Elevacity brand, so named to signify the company’s commitment to elevating lives.

The Elevate health and wellness product line consists of nutraceutical products that SHRG refers to as D.O.S.E., which stands for dopamine, oxytocin, serotonin and endorphins – all of which are key hormones proven to promote happiness and well-being.

Elevacity brand products are carefully formulated, chosen and designed to support a single objective: elevate the happiness and well-being of the consumer.

Global Network of Elepreneurs

Elevacity products are shared and sold by a growing international network of home-based entrepreneurs, called Elepreneurs, operated by Elepreneurs Holdings. This SHRG subsidiary provides basic and advanced programs for both new and experienced entrepreneurs who are focusing on their direct-sales careers.

SHRG’s high-performing independent sales force follows the company’s Blue Ocean selling strategy, an approach that encourages individuals to seek new markets, lead, and to “stop competing and start creating.” The Blue Ocean strategy is based on the book, “Blue Ocean Strategy,” written by Professor Renée Mauborgne, who notes that “the lesson here is that the best defense is offense, and the best offense… is to make a blue ocean shift and create your own blue ocean.”

Following this selling strategy, SHRG’s Elepreneurs are taught that, rather than competing directly in a competitive, direct-selling market, they should focus on making competitors irrelevant and succeeding in an uncontested marketplace.

In addition, SHRG’s Elepreneurs use the interactive, video-based VERB sales-marketing platform developed by Verb Technology Company Inc. The app utilizes proprietary interactive video data collection and analysis technology and provides next-generation customer relationship management, lead generation, and video marketing software applications.

Continued Momentum as Industry Leader

These selling strategies have resulted in sharp and consistent revenue gains. In the company’s 10-Q filed with the SEC for the three months ended Oct. 31, 2019, SHRG reported sales of $38.8 million for fiscal Q2 2019, an increase of 116% over sales of $17.9 million reported for the comparable quarter of 2018. Consolidated gross profit jumped by $16.2 million to $27.4 million for the same period compared to Q2 2018.

SHRG’s consolidated operating earnings were $3.9 million in the fiscal quarter ended Oct. 31, 2019, compared to $866,802 for the comparable period the prior year. Consolidated gross margin also grew 70.9% for the three months ended Oct. 31, 2019, compared to 62.2% the prior year.

These numbers are continuing a trend established over the past two years. In fiscal Q1 2019, SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018. Even earlier, the company reported sales of $85.9 million for fiscal year ended April 30, 2019. This represents a nine-fold increase, or $77.5 million jump, over the company’s revenues of $8.4 million the prior year.

These numbers bring SHRG’s sales revenues since December 2017 — when the company’s Elevate product line was released — to an impressive cumulative total of $169 million.

Preparing for Success

SHRG is well prepared to continue and accommodate for this growth. The company recently expanded its corporate footprint by moving to a 10,000-square-foot facility in Plano, Texas, that offers ample room to expand as the company grows and flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

In addition, the company has a seasoned, expert leadership team in place, led by John “JT” Thatch. Thatch was appointed president and CEO of SHRG in March 2018, bringing to the company his expertise obtained from successfully starting, owning and operating several businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist SHRG as the company aims to expand and increase revenues.

Contact
469.304.9400 x 201
Info@SHRGinc.com
http://www.SHRGinc.com

Sharing Services Global Corporation (SHRG), closed Wednesday's trading session at $0.053, off by 24.3937%, on 5,658,249 volume with 170 trades. The average volume for the last 3 months is 184,765 and the stock's 52-week low/high is $0.035/$0.3944.

Recent News

SinglePoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

SinglePoint, Inc. (SING) was featured today in a publication from CBDWire, examining how the past few months have seen an uptick in the number of studies looking into cannabidiol’s (CBD) medical abilities. At the moment, there’s tons of anecdotal evidence in support of CBD, and users claim it’s effective against everything from insomnia and anxiety to high blood pressure and chronic pain. There have also been inroads in CBD products for pets, but the consensus is that more research is needed before cannabidiol can be Okayed.

SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed Wednesday's trading session at $0.011375, off by 3.6017%, on 9,348,995 volume with 290 trades. The average volume for the last 3 months is 3,561,874 and the stock's 52-week low/high is $0.007/$0.023.

Recent News

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman Holdings (TSX: TGOD) (OTCQX: TGODF), a leading producer of premium, certified-organic cannabis, this morning announced that it has received a research license from Health Canada. The license is valid for five years and enables TGODF to cut the costs and quicken the pace of the development of new products by removing its need to rely on third parties. To view the full press release, visit http://cnw.fm/Go8eP. Also today, the company was highlighted in the Investor Ideas Potcast, from Investorideas.com. Listen to the podcast: http://ibn.fm/feJu8.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed Wednesday's trading session at $0.423, up 3.02%, on 576,750 volume with 313 trades. The average volume for the last 3 months is 1,237,977 and the stock's 52-week low/high is $0.409999996/$4.38000011.

Recent News

Neutra Corp. (OTCQB: NTRR)

The QualityStocks Daily Newsletter would like to spotlight Neutra Corp. (NTRR).

Neutra Corp. (NTRR) continues its efforts towards vertical integration, this time examining the potential of integrating technology into its hemp-based CBD enterprise. The company believes the time is right to add a technological dimension to its operation and that such an addition could lead to greater future growth and expansion opportunities.

Neutra Corp. (OTCQB: NTRR) is an early-stage research and development company bringing modern healthy living solutions to a multi-billion-dollar market. Cutting-edge technologies within the nutraceuticals, food and drug, and environmental purification sectors are creating a new kind of world culture – one where consumers are demanding access to products that promote health and stave off potential health dangers.

Neutra is concentrating on developing into a vertically integrated company able to cultivate, manufacture and distribute hemp-based cannabidiol (CBD) products. Hemp-based CBD consumer products generated sales of up to $390 million in 2018 with projections pointing to a $3 billion market by 2022, according to the Hemp Business Journal.

Neutra’s new broadened scope, which includes the commercialization of newer, more effective products, aims to capitalize on this worldwide boom. Our company is seeking new and exciting opportunities that can accelerate Neutra’s mission to bring these products to a wider demographic. Our work reflects a renewed dedication to supporting a better body, environment and life for people around the globe.

Acquisitions

  • VIVIS – Neutra continues to expand its market presence in the rapidly growing hemp-derived CBD market and recently acquired VIVIS, an emerging retail brand of hemp-based health and nutritional products. VIVIS’ hemp-derived CBD products are third-party certified as contaminant-free and of consistent quality and potency. Consumers are increasingly looking for this certification when they buy hemp-based CBD products. With VIVIS as the new retail face of Neutra, the company is expecting greater interest in its expanding portfolio of branded products moving to market.
  • J3 Holdings – The signing of a letter of intent to acquire J3 Holdings includes the company’s land and warehouse, as well as a license to cultivate hemp and refine it into usable forms. Neutra has concentrated its early efforts developing business networks and on developing hemp-based CBD products, including supplements and creams. The latest move will enable the company to grow its own hemp supply, giving it more control over the quality of its ingredients.

Partners

  • Surface to Air Solutions is the North American distributor of a patent-pending, water-based solution known as Purteq, a green technology that works similar to photosynthesis.
  • ZeroBlast uses a durable, non-toxic, anti-microbial solution to eliminate all contaminates and kill germs on contact for a period of up to 90 days.

Leadership

Neutra president and CEO Sydney Jim provides strong executive leadership, a network of business contacts and experience implementing solid corporate strategy. Jim has a proven track record of adding value for public company shareholders. He founded Global Visionary Investments where operational support is provided to seven different companies and their subsidiaries. Jim was also the CEO of First Titan Energy, a microcap public company where he was responsible for restructuring the corporate structure, deal sourcing, and leading the company in mergers and acquisitions.

Dr. Scott Cherry is the company’s sports performance medical advisor. He is an energetic physician executive with a passionate focus on health, performance and prevention. Dr. Cherry received emergency medical technician training in the U.S. Navy, a bachelor’s degree in chemistry from Florida State University, medical degree from Nova Southeastern University, and a master’s degree of public health from Uniformed Services University F. Edward Herbert School of Medicine. Dr. Cherry has honed his skills in a variety of medical and executive positions spanning the U.S. Army and Navy, several Fortune 500 corporations, and major health care facilities over the past 20 years.

Neutra Corp. (OTCQB: NTRR), closed Wednesday's trading session at $0.0008, up 14.2857%, on 4,213,863 volume with 19 trades. The average volume for the last 3 months is 15,646,514 and the stock's 52-week low/high is $0.0005/$0.028799999.

Recent News

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Genprex, Inc. (Nasdaq: GNPX), a clinical stage gene therapy company developing a new and potentially life-saving approach to treating some of the world’s most deadly cancers based upon a novel proprietary technology platform, today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 5,000,000 shares of common stock, par value $0.001 per share, at an offering price of $3.50 per share, pursuant to a registered direct offering, priced at-the-market under Nasdaq rules.

Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed Wednesday's trading session at $3.90, off by 20.4082%, on 17,444,905 volume with 59,970 trades. The average volume for the last 3 months is 6,245,188 and the stock's 52-week low/high is $0.231000006/$5.75.

Recent News

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

Supreme Cannabis Company Inc. (TSX: FIRE) (OTC: SPRWF) is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees and culture of innovation. The company aims to grow the world’s best legal cannabis and become a leader in the global industry. Supreme Cannabis calls its Toronto Venture Exchange stock symbol, “FIRE,” a testament to the company’s passion for cannabis and obsession with quality.

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as one of Canada’s most premium cannabis producers, the company sees itself at the center of this global shift.

A key piece of Supreme Cannabis’ ability to fulfill its mission is its flagship brand, 7ACRES, a wholly owned subsidiary that operates a 440,000-square-foot hybrid cultivation facility in Kincardine, Ontario. 7ACRES is focused on building a core competency in scaled high-quality cannabis production. With a best-in-class cultivation facility producing a competitive product that fuels a leading premium brand, Supreme Cannabis has achieved a differentiated advantage in cultivation IP, products and branding. The company’s foundational investment in premium cultivation has secured it a leadership position in the industry as the Canadian market becomes more competitive and matures.

Since legalization, 7ACRES has brought five premium flower strains to market in Canada. The demand for 7ACRES product continues with the company’s most recent launch of Jack Haze, a new proprietary premium cultivar. The company’s first sativa-dominant strain, Jack Haze offers rare sensory characteristics, delivering high THC content with a terpinolene forward profile, including a complex aroma with notes of citrus, pine and warm spice. As it develops its next winning strain, 7ACRES continues to prioritize subjective quality. In the Canadian cannabis market, this approach has established 7ACRES as a well-known premium brand that commands premium pricing coast-to-coast.

In addition to 7ACRES, Supreme Cannabis has built a diversified portfolio of focused consumer-driven brands:

  • Sugarleaf by 7AC – this new brand widens Supreme Cannabis’ product offerings and targets consumers who are looking for more refined, milder consumption experience as they discover their own cannabis taste preferences and desires. Product formats under this brand are focused on offering consumers elegant and convenient cannabis experiences.
  • Blissco — dedicated to providing wellness focused consumers with premium cannabis products, education, and outstanding customer care. Blissco is focused on bringing its collection of premium whole-flower CBD oils to market.
  • Truverra — focused on being a global leader in the development, production and marketing of hemp and cannabis-derived medicinal products with clinically proven efficacy. With over 25 SKUs sold online in the UK and Europe, Truverra is ideally positioned to address emerging international cannabis opportunities.
  • Khalifa Kush Enterprises — formed through a prestigious international partnership with Khalifa Kush Enterprises (KKE) Canada, the Canadian counterpart to the popular U.S. cannabis brand KKE formed by Wiz Khalifa. Together, Supreme Cannabis and KKE Canada are developing and launching a lineup of premium cannabis products, including a future line based on the well-known Khalifa Kush strain.

Each of Supreme Cannabs’ brands and partnerships have been strategically identified and designed to support the company’s mission to enhance the lives of consumers through positive cannabis experiences. Equally important to delivering desirable consumer experiences is the infrastructure supporting the company’s brands and products. From seed to sale, supreme cannabis continues to build an impressive group of operating assets that serve key functions throughout the value chain:

  • Cultivation – for starters, there is Supreme Cannabis’ foundational flagship asset, its 440,000-square-foot cultivation facility in Kincardine, Ontario. With over 600 employees, 24 grow rooms, and best-in-class processing equipment and procedures, this facility is expected to reach an annual production capacity of 50,000 kilograms in the near-term. In this purpose-built facility, the company grows small-batch high-quality cannabis from 10,000-square-foot grow rooms and completes a proprietary hang-dry for up to two weeks.
  • Extraction – with the acquisition of Blissco in fiscal 2019, in addition to the Blissco wellness brand, Supreme Cannabis gained a 12,000-square-foot dedicated extraction facility in Langley, BC. This facility conducts both C02 and ethanol extraction and with the recent receipt of its oil sales license from Health Canada, it now produces Blissco branded CBD oils and expects to fill vaporizer pods for a partnership between the company’s 7ACRES brand and Pax Labs.
  • Manufacturing – most recently, the company announced its 107,000-square-foot processing, packaging and manufacturing facility in Kitchener, naming the facility Supreme Cannabis Kitchener. In Q4 FY2020, the company expects to begin whole flower packaging and pre-roll manufacturing for Supreme Cannabis brands at the Kitchener Facility. In the long-term, in additional to processing its own inputs, Supreme Cannabis intends generate incremental revenue by packaging, distributing and branding third-party cannabis inputs from quality-focused cultivators.
  • R&D and Product Testing – In Q1 FY2020, Supreme Cannabis closed the acquisition of Truverra and acquired a 5,000-square-foot facility licensed under Canadian Clinical Cannabinoids Inc. in Scarborough, Ontario (“Supreme Cannabis Scarborough”). Supreme Cannabis Scarborough provides R&D space for the company to test new products and develop medicinal science intellectual property. In the near-term, with the legalization of 2.0 cannabis products, this centre for innovation will be testing and bringing concentrate products to market under the 7ACRES brand.

Supreme is committed to continue to identify new opportunities to grow and strengthen its impressive portfolio of operating assets and brands and scale its strong Canadian business globally.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed Wednesday's trading session at $0.289885, up 1.0052%, on 400,923 volume with 230 trades. The average volume for the last 3 months is 480,354 and the stock's 52-week low/high is $0.27000001/$1.75.

Recent News

Jerrick Media Holdings, Inc. (OTC: JMDA)

The QualityStocks Daily Newsletter would like to spotlight Jerrick Media Holdings, Inc. (OTC: JMDA).

Jerrick Media Holdings, Inc. (OTC: JMDA) develops technology-based solutions to solve digital problems. Through the combination of design, thought and data analysis, the company builds products that influence a worldwide audience.

Jerrick’s flagship product is Vocal, a proprietary long-form digital publishing platform that provides storytelling tools and engaged communities for creators to get discovered and fund their creativity.

Vocal

Designed to develop and cost-effectively engage content creators, the Vocal platform enables its over 500,000 registered content creators to reach an engaged audience and monetize their content. In addition to providing relevant content, Vocal’s technology is centered on efficiency and scalability through its niche digital communities, as well as output through its data-driven distribution strategy.

Vocal partners with content creators and brands that recognize difficulties inherent in the digital advertising space and that can benefit from branded content marketing opportunities available on publishing platforms like Vocal.

All content available on Vocal is created within the platform’s custom editor and published on one of Vocal’s embedded genre-specific communities, spanning topics that range from food to wellness, beauty, technology and more.

In May 2019, Jerrick launched Vocal+, its premium subscription membership program. Vocal+ members pay a membership fee for premium value-added features, including receiving increased earnings for their content, reduced platform processing fees for tips received, a Vocal+ badge on their creator page, access to new features on the Vocal Platform, and other rewards. Creators can sign up for free or upgrade to Vocal+, available for purchase on either an annual or monthly subscription basis.

 

Vocal for Brands

Vocal for Brands is an in-house creative studio that generates actionable data from bespoke native advertising campaigns. Vocal for Brands partners with direct-to-consumer (DTC) to create beautiful, campaign-optimized stories on Vocal that build brand affinity, trust and drive results.

Additionally, Jerrick provides a Managed Services offering to business-to-business (B2B) and business-to-consumer (B2C) product and service brands which encompasses a full range of digital marketing and e-commerce solutions. Managed Services includes the setup and ongoing maintenance of clients’ websites, Amazon and Shopify storefronts and listings, social media pages, search engine marketing, and other various tools and sales channels utilized by e-commerce sellers for sales and growth optimization. In addition to partnering with Managed Services clients, the company offers a range of la carte services.

Growth Strategy

Upon the consummation of its anticipated listing on the Nasdaq Capital Market, Jerrick intends to change its official company name to “Creatd, Inc.,” subject to stockholder approval.

This rebranding will initiate Jerrick’s go-forward growth strategy and its plans to expand its offerings and provide technology products and resources for creators to help transform their ideas into reality. The strategic plan is designed to greatly increase Jerrick’s potential market value via a plethora of new revenue streams.

Creatd will focus on a community of creators that number more than 2.5 billion users, for which it will offer democratized, transparent platforms for distribution, sentiment, resources and monetization. The company’s agile development process will rely on a combination of bleeding-edge technology that eliminates barriers and creates efficiencies. Superior design thinking and data analysis will allow Creatd to expand its digital footprint to a global community.

Creatd will partner with a community of technology collaborators and sophisticated investors who collaborate to provide technology solutions for creators, brands and their respective audiences. The company’s solutions, business processes, technology platforms and design theories will lend themselves to application opportunities on a global scale.

History & Management

Jerrick was founded in 2012. Initially a private media company providing online content through a portfolio of brands, Jerrick’s needs quickly outpaced its initial technology and product offering. In 2015, Jerrick partnered with Thinkmill, a premiere, Australia-based product design and development group to create a content management system (CMS) for its brands; that system evolved into the company’s flagship product, Vocal.

Today, Jerrick’s management team is an impressive group of abstract thinkers united by their passion to solve problems. Leading the team are founder and CEO Jeremy Frommer, and Justin Maury, Jerrick’s president and head of product.

Frommer’s career includes two decades in the financial technology industry, working as a hedge fund and portfolio manager, as well as on the sell-side of the financial industry. Frommer started NextGen Trading, a software development company building proprietary equity trading platforms. NextGen was acquired by Carlin Financial Group of which Frommer became CEO. RBC Capital Markets Corporation eventually bought Carlin. At RBC, Frommer was managing director, head of the Global Prime Services group and a member of the RBC Global Equities Operating Committee.

Maury joined Jerrick in 2013, bringing with him 10 years of experience in the creative industry. Since partnering with Frommer to establish Jerrick, Maury led the company’s product development for more than four years. His passion for the creative arts and technology ultimately yielded the vision for Vocal. During the Jerrick’s early formative years, Maury was a driving force in creating the vision, design and architecture for the Vocal platform and managing the oversight of technology development.

Jerrick Media Holdings, Inc. (JMDA), closed Wednesday's trading session at $3.75, even for the day, on 2,000 volume. The average volume for the last 3 months is 1,112 and the stock's 52-week low/high is $1.63999998/$5.00.

Recent News

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Wednesday's trading session at $2.32, off by 2.521%, on 14,637 volume with 25 trades. The average volume for the last 3 months is 19,903 and the stock's 52-week low/high is $0.600600004/$4.0300002.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.